CLINICAL RESEARCH TO UNDERSTAND ACQUIRED IMMUNITY TO DENGUE VIRUSES
Funder
National Health and Medical Research Council
Funding Amount
$841,953.00
Summary
Dengue, the commonest arboviral disease of humans, is caused by any of the four serotypes of dengue virus (DENV-1-4). This clinical research project will explore how acquired immunity to dengue viruses is expressed. The results will help dengue vaccine developers make better vaccines for use in Australian travellers and in dengue endemic countries in SE Asia.
Chimeric Insect-specific Flaviviruses: A New Generation Of Diagnostics And Vaccines Against Mosquito-borne Viral Disease
Funder
National Health and Medical Research Council
Funding Amount
$549,937.00
Summary
Dengue, Zika and West Nile are mosquito-borne viruses that cause disease outbreaks world-wide. We will develop safe, cheap and authentic diagnostics and vaccines against these diseases based on novel viruses that only infect mosquitoes. This is a timely paradigm shift for vaccine and diagnostic development. This innovative strategy will have high impact in the field of vector-borne viral diseases and provide a blueprint to develop safe diagnostics and vaccines for other mosquito-borne diseases.
The Dengue Virus Glycoprotein NS1 Binds Cholesterol And Mediates Cellular Activation
Funder
National Health and Medical Research Council
Funding Amount
$632,029.00
Summary
Cholesterol has been shown to play a vital role in the life cycle of many viruses. This project will investigate the basis of dengue virus interaction with this important host molecule and along with investigations of how dengue is able to stimulate host cells, will provide new insights into the way these viruses cause severe disease. Findings from this study will also aid in the development of new drug strategies for dengue and related viruses such as West Nile virus.
Needle Free Delivery Of Dengue And Zika Vaccines To The Skin
Funder
National Health and Medical Research Council
Funding Amount
$642,792.00
Summary
There is no Zika vaccine and only one licensed dengue vaccine, which is age and region restricted because of poor efficacy. We have developed safe subunit vaccine candidates capable of inducing potent virus neutralizing antibodies and demonstrated protection from lethal dengue challenge in a mouse model. Here we are partnering with Vaxxas to undertake preclinical development and GLP toxicity trials for microarray patches delivering dengue and zika virus subunit vaccines.
Dengue Host-cell Signalling Interactions: Novel Insights And Interventions
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
Dengue is a virus transmitted by mosquitoes that occurs in many tropical and subtropical regions. Approximately 40% of the world's population is at risk of this infection. Sometimes it can be mild but it can lead to severe illness and death especially with second infections. The body produces a response that over-reacts to the virus in these severe infections. The project aims to understand why the body does this and what parts of the immune system are affected using a model in mice.
Arbovirus Activation And Modulation Of NLRP3 Inflammasome
Funder
National Health and Medical Research Council
Funding Amount
$779,720.00
Summary
This project aims to establish how mosquito borne viruses such as Ross River and dengue viruses interacts with the human host to cause disease, including how the virus evades the host’s immune response to persist and cause disease for prolonged periods. Knowing how differences in the virus and the host’s immune system interplay to cause asymptomatic to severely disabling disease will assist in devising new treatments and prevention programs to lessen the impact of these diseases in Australia.
Dengue is a serious viral disease that is spread by mosquitoes. Dengue results in hundreds of thousands of children and young adults being hospitalized in Asia every year, and some patients die. There is no vaccine or specific treatment. In this fellowship I will lead a research program that aims provide doctors with the tools to diagnosis and treat dengue more efficiently and to develop a novel biological control to prevent dengue being transmitted by mosquitoes.
Dengue virus is the most important mosquito-borne viral disease, with 2/3 of the world's population at risk. There is currently no treatment available for dengue. Our proposal aims to progress a safe and effective new treatment (4-HPR) against Dengue towards the clinic, generating all the required pharmacokinetic and pre-clinical animal data necessary to progress to a future clinical trial in humans. We will also investigate the use of 4-HPR as a dengue preventative.
Dengue Virus NS1 Protein As A Mediator Of Pathology
Funder
National Health and Medical Research Council
Funding Amount
$621,979.00
Summary
Dengue virus is an increasing problem in the tropical world, with estimated infection of more than 300 million people annually. Severe dengue disease can cause life-threatening bleeding and shock. Our project investigates the basis for the pathology of the disease. We have found that a viral protein termed NS1 binds to a receptor on immune cells and leads to production of inflammatory proteins which can promote vessel leakage. We will investigate drugs blocking this, in a disease model.
Roles And Regulation Of Sphingosine Kinase 1 During Dengue Virus Infection
Funder
National Health and Medical Research Council
Funding Amount
$482,795.00
Summary
Dengue virus (DENV) infection is a global human disease with an estimated 50 million infections annually and there is no vaccine or therapy. DENV disease is worsended by the way the body responds to infection and we have investigated these responses. We know the virus changes a molecule in the body called sphingosine-kinase 1 (SK1), which normally controls if cell live or die and how they function. This study will characterise how DENV influences SK1 and if we can target this interaction to deve ....Dengue virus (DENV) infection is a global human disease with an estimated 50 million infections annually and there is no vaccine or therapy. DENV disease is worsended by the way the body responds to infection and we have investigated these responses. We know the virus changes a molecule in the body called sphingosine-kinase 1 (SK1), which normally controls if cell live or die and how they function. This study will characterise how DENV influences SK1 and if we can target this interaction to develop new drugs against DENV infection.Read moreRead less